Promising Phase 2 Results for Efgartigimod alfa-fcab in Adults with Primary Sjögren’s Disease Michele B. Kaufman, PharmD, BCGP | August 26, 2025A study from Peene et al. found that patients with primary Sjögren’s disease experienced significant improvements in systemic disease activity and symptoms when treated with intravenous efgartigimod alfa-fcab.